EUVIMEDEUVIMED entdecken
MetaanalyseOpen Access · CC BY 4.0

UGT1A4*3 polymorphism influences serum concentration and therapeutic effect of lamotrigine for epilepsy treatment: A meta-analysis

Zhimei Jiang, Yuzhi Fu, Hongxin Shen iD

PLOS ONE · 18.07.2024 · 19 (7) · e0307377

DOI: 10.1371/journal.pone.0307377 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift PLOS ONE, online erschienen am 18.07.2024. Verfasst von Zhimei Jiang und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, West China Second University Hospital of Sichuan University, Chengdu, China. Hauptthemen laut MEDLINE: Lamotrigine, Glucuronosyltransferase, Epilepsy, Anticonvulsants. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Lamotrigine as a broad-spectrum antiepileptic drug, is widely applied and its clinical efficacy is highly recognized. However, significant differences are observed in blood drug concentration of lamotrigine among individuals, which may have an impact on its efficacy. UGT1A4 is the main metabolic enzyme. However, it was inconsistent for the influence of UGT1A4 genetic polymorphism on concentration and efficacy of lamotrigine therapy. This study aimed to evaluate the influences of UGT1A4*3 genetic polymorphisms on lamotrigine concentration and therapeutic effect through meta-analysis.

Methods

The literature search was conducted in Medline, Embase, PubMed, Web of Science, Wan Fang Database, China National Knowledge Infrastructure, China Science and Technology Journal Database until January 2024. The primary outcome included the mean serum concentration, concentration-to-dose-ratio by body weight (CDR), or efficacy related to different UGT1A4*3 genotype for lamotrigine therapy. Data were collected to access the Mean Difference or odds ratio with 95% confidence interval. Meta-analysis was performed by RevMan 5.2.

Results

A total of eleven studies were enrolled. The meta-analysis for mean serum concentration of lamotrigine showed no significant difference between patients carrying TT genotypes and TG and GG genotypes group (MD: 0.12, 95% [-0.35, 0.58], P = 0.62). There was significant difference in CDR (MD: 0.49, 95% [0.03, 0.94], P = 0.04) and therapeutic efficacy (OR: 7.18, 95% [4.01, 12.83], P

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LamotrigineGlucuronosyltransferaseEpilepsyAnticonvulsantsHumansPolymorphism, GeneticGenotypePolymorphism, Single NucleotideTreatment Outcome

Substanzen

LamotrigineGlucuronosyltransferasebilirubin glucuronoside glucuronosyltransferaseAnticonvulsants

Autor:innen und Institutionen

  • Department of Pharmacy, West China Second University Hospital of Sichuan University, Chengdu, China.
  • Evidence-Based Pharmacy Center, West China Second University Hospital of Sichuan University, Chengdu, China.
  • Key Laboratory of Birth Defects and Related Diseases of Women and Children, Ministry of Education, Sichuan University, Chengdu, China.

ORCID-Profile: Hongxin Shen

Zitieren

APA

Jiang, Z., Fu, Y., & Shen, H. (2024). UGT1A4*3 polymorphism influences serum concentration and therapeutic effect of lamotrigine for epilepsy treatment: A meta-analysis. PLOS ONE, 19(7), e0307377. https://doi.org/10.1371/journal.pone.0307377

Vancouver

Jiang Z, Fu Y, Shen H. UGT1A4*3 polymorphism influences serum concentration and therapeutic effect of lamotrigine for epilepsy treatment: A meta-analysis. PLOS ONE. 2024;19(7):e0307377. doi:10.1371/journal.pone.0307377

BibTeX
@article{Jiang2024,
  author = {Jiang, Zhimei and Fu, Yuzhi and Shen, Hongxin},
  title = {UGT1A4*3 polymorphism influences serum concentration and therapeutic effect of lamotrigine for epilepsy treatment: A meta-analysis},
  journal = {PLOS ONE},
  year = {2024},
  volume = {19},
  number = {7},
  pages = {e0307377},
  doi = {10.1371/journal.pone.0307377}
}
Kostenlos starten →